newsfilter
← Latest News
GlobeNewswire·

Nyxoah to Participate in the Bank of America 2026 Healthcare Conference

NYXH
  • Nyxoah SA will participate in the Bank of America 2026 Healthcare Conference on Wednesday, May 13, 2026.
  • The company's presentation is scheduled for 5:15 pm Eastern Time on the conference date via webcast.
  • Nyxoah will offer one-on-one meetings with institutional investors attending the event.
  • The company's lead product is the Genio system, a leadless, battery-free hypoglossal neurostimulation therapy for Obstructive Sleep Apnea (OSA).
  • The Genio system received its European CE Mark in 2019 following the BLAST OSA study.
  • Nyxoah completed IPOs on Euronext Brussels in September 2020 and on NASDAQ in July 2021.
  • Positive BETTER SLEEP study outcomes led to CE mark approval for Complete Concentric Collapse (CCC) patients.
  • The FDA approved the Genio system in August 2025 for adults with moderate to severe OSA (AHI ≥15 \& ≤65) following the DREAM IDE pivotal study.
  • Nyxoah received FDA approval as a prescription-only device in August 2025.
  • The company plans to expand its commercialization strategy & entrance into the U.S. market.